Peer-reviewed veterinary case report
How protein markers relate to dog mammary tumors
By Yoshida, Kota et al.·Published in The Journal of veterinary medical science·2014·Graduate School of Agricultural and Life Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The relationship between clinicopathological features and expression of epithelial and mesenchymal markers in spontaneous canine mammary gland tumors.
- Species:
- dog
Plain-English summary
A study looked at 119 dogs with mammary tumors to understand how certain protein markers relate to the severity of the tumors. They found that malignant tumors often showed a loss of specific proteins called ZO-1 and E-cadherin, while gaining others like vimentin and N-cadherin. Notably, dogs with lower levels of E-cadherin had a significantly lower chance of surviving for a year. This suggests that the presence of E-cadherin could be an important factor in determining how aggressive a mammary tumor is in dogs.
People also search for: dog mammary tumor survival rate · canine mammary cancer treatment · E-cadherin in dog tumors
Abstract
It is known that epithelial mesenchymal transition (EMT) contributes to the acquisition of malignant property in human cancers. However, the role of EMT in canine tumors remains to be elucidated. To evaluate the correlation between expression levels of protein markers involved in EMT and clinicopathological characteristics in canine mammary gland tumors, immunohistochemistry using antibodies against ZO-1, E-cadherin, vimentin, N-cadherin and fibronectin was performed on 119 clinical tissue samples. Consequently, loss of ZO-1 and E-cadherin, and gain of vimentin and N-cadherin were more frequently observed in malignant tumors than in benign tumors. However, there was no correlation among expression of these molecules. Univariate and multivariate analysis identified that loss of E-cadherin independently had a low one-year survival rate (adjusted odds ratio: 2.3, P=0.02). These results suggested that EMT might relate to acquisition of malignancy, and additionally, E-cadherin was strongly correlated with malignant behavior in canine mammary gland tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24931646/